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Abstract
Background:  Methylphenidate (MPD) is a psychostimulant commonly prescribed for attention deficit/
hyperactivity disorder. The mode of action of the brain circuitry responsible for initiating the animals' behavior in
response to psychostimulants is not well understood. There is some evidence that psychostimulants activate the
ventral tegmental area (VTA), nucleus accumbens (NAc), and prefrontal cortex (PFC).
Methods: The present study was designed to investigate the acute dose-response of MPD (0.6, 2.5, and 10.0 mg/
kg) on locomotor behavior and sensory evoked potentials recorded from the VTA, NAc, and PFC in freely
behaving rats previously implanted with permanent electrodes. For locomotor behavior, adult male Wistar-Kyoto
(WKY; n = 39) rats were given saline on experimental day 1 and either saline or an acute injection of MPD (0.6,
2.5, or 10.0 mg/kg, i.p.) on experimental day 2. Locomotor activity was recorded for 2-h post injection on both
days using an automated, computerized activity monitoring system. Electrophysiological recordings were also
performed in the adult male WKY rats (n = 10). Five to seven days after the rats had recovered from the
implantation of electrodes, each rat was placed in a sound-insulated, electrophysiological test chamber where its
sensory evoked field potentials were recorded before and after saline and 0.6, 2.5, and 10.0 mg/kg MPD injection.
Time interval between injections was 90 min.
Results: Results showed an increase in locomotion with dose-response characteristics, while a dose-response
decrease in amplitude of the components of sensory evoked field responses of the VTA, NAc, and PFC neurons.
For example, the P3 component of the sensory evoked field response of the VTA decreased by 19.8% ± 7.4%
from baseline after treatment of 0.6 mg/kg MPD, 37.8% ± 5.9% after 2.5 mg/kg MPD, and 56.5% ± 3.9% after 10
mg/kg MPD. Greater attenuation from baseline was observed in the NAc and PFC. Differences in the intensity of
MPD-induced attenuation were also found among these brain areas.
Conclusion: These results suggest that an acute treatment of MPD produces electrophysiologically detectable
alterations at the neuronal level, as well as observable, behavioral responses. The present study is the first to
investigate the acute dose-response effects of MPD on behavior in terms of locomotor activity and in the brain
involving the sensory inputs of VTA, NAc, and PFC neurons in intact, non-anesthetized, freely behaving rats
previously implanted with permanent electrodes.
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Background
Methylphenidate (MPD), also known as Ritalin, is a psy-
chomotor stimulant of the central nervous system (CNS)
that has a similar chemical structure to amphetamine and
methamphetamine [1-3]. It has been reported that an esti-
mated 20 million monthly prescriptions for analeptic
medications were written for the treatment of attention
deficit/hyperactivity disorder (ADHD) [4], of which MPD
was the most frequently prescribed medication [5,6]. The
drug has been shown to block the dopamine transporter
(DAT) and thereby elevates extracellular dopamine (DA)
levels in the ventral tegmental area (VTA), nucleus
accumbens (NAc), and prefrontal cortex (PFC), which are
brain areas of the mesocorticolimbic DA system involved
in the locomotor and reinforcing effects of psychostimu-
lants and other drugs of abuse [7-13]. A neuroimaging
study indicated that MPD shares similar in vivo potency as
cocaine in blocking the DAT in human brain [14]. Despite
the escalating consumption of MPD [15,16] and the fact
that MPD has many of the same neuropharmacological
effects as amphetamine and cocaine [14,17], the adverse
effects of MPD treatment in children and adults remain
controversial. Some studies have correlated ADHD with
subsequent substance abuse [18-20], while other studies
have reported that pharmacotherapy of ADHD reduces
the risk for substance abuse [21,22].
Although MPD potently attenuates the hyperactivity,
impulsivity, and inattention in 60–90% of ADHD cases,
the optimal dosages of the drug have not yet been estab-
lished [23,24]. Currently, there is not any empirical data
to consistently show linear improvements with dose
[25,26] and the adverse effects of high dose levels of MPD
[27-29].
To assess differential effects of MPD dosage, it is impor-
tant to evaluate the effects on the brain itself and on the
whole animal, that is, behavior [29]. However, few studies
have investigated the neurophysiological properties of
psychostimulants, such as MPD, in intact humans or ani-
mals [30], especially its behavioral effects and alteration
of sensory evoked neuronal activity in brain regions that
are involved in the mesocorticolimbic DA system. Most
neurophysiological studies that investigated psychostim-
ulants have been conducted in vivo in the presence of
anesthesia [4,31,32], which is known to interfere with
CNS activity [33], or obtained in vitro on brain slices [34-
38]. A valuable method to studying the mechanistic
action of psychostimulants, such as MPD, on neuronal
population is to record neuronal activity before and after
administration of the psychostimulant in an intact, non-
anesthetized, freely behaving subject through sensory-
evoked field responses following sensory stimulation.
During such recording, on-going physiological events
occurring before and after drug administration in specific
brain sites can be examined without any anesthetic inter-
ference. Thus, simultaneous recordings of neuronal activ-
ity from brain regions identified as sites for MPD action
are very important and warrant further investigations. It
provides the opportunity to study information processing
in millisecond temporal resolution time locked to the
occurrence of the stimulus [39]. The objective of the
present study was to determine the acute dose-response
effects of MPD on sensory evoked potentials recorded
from the VTA, NAc, and PFC following an acoustic stimu-
lus in intact, non-anesthetized freely behaving rats previ-
ously implanted with permanent electrodes and
correlating these neuronal effects to the rat's locomotor
behavior.
Results
Behavior – locomotor activity testing
Figure 1 summarizes the dose response of adult male WKY
rats to an acute administration of 0.6, 2.5, and 10.0 mg/
kg MPD as compared to the control rats that received
saline. Values are presented as the mean + S.E.M., where at
least *p < 0.05. There was no significant difference in the
horizontal and vertical activities of the saline treated rats
on experimental day 1 and day 2. Similarly, there was also
no significant difference in these motor indices of rats that
received saline on experimental day 1 and 0.6 mg/kg MPD
on experimental day 2. However, a single injection of 2.5
mg/kg MPD significantly increased the horizontal [F1,15 =
6.459, p = 0.024] and vertical [F1,15 = 6.097, p = 0.027]
activities on experimental day 2 when compared to saline
on experimental day 1. The 10 mg/kg MPD dose elicited a
significantly further augmentation (p < 0.01) as compared
to the 2.5 mg/kg dose in both of these locomotor indices
(horizontal activity [F1,15 = 117.77, p = 0.00]; vertical
activity [F1,15 = 126, p = 0.00]) on experimental day 2
when compared to day 1, on which the rats received
saline.
Sensory evoked potential recording
Fifty acoustic evoked responses were averaged. Four such
averages were performed before and after each injection.
Figure 2 shows a representative of the averaged (n = 50)
sensory (acoustic) evoked field potential recorded simul-
taneously in the VTA, NAc, and PFC following the admin-
istration of saline (baseline) and a single injection of 0.6,
2.5, and 10 mg/kg, i.p., MPD. All three MPD doses atten-
uated the amplitude of the field potential components
(P2, N2, and P3) as compared to those of baseline in the
VTA, NAc, and PFC neurons. All recordings were obtained
20 min post-injection of saline and MPD. It became evi-
dent that the 0.6 mg/kg MPD that failed to alter locomo-
tion attenuated the acoustic average of evoked responses.
Moreover, the higher MPD doses that had increased loco-
motor behavior further attenuated the averaged sensory
evoked responses in the VTA, NAc, and PFC (Fig. 2).Behavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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summarizes the dose response of adult male WKY rats to an acute administration of 0.6 (n = 8), 2.5 (n = 8), and 10.0 (n = 8)  mg/kg MPD as compared to the control rats that received saline (n = 8) Figure 1
summarizes the dose response of adult male WKY rats to an acute administration of 0.6 (n = 8), 2.5 (n = 8), and 10.0 (n = 8) 
mg/kg MPD as compared to the control rats that received saline (n = 8). Values are presented as the mean + S.E.M., where at 
least *p < 0.05.Behavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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Figure 3 summarizes the percent decrease in amplitude of
the sensory (acoustic) evoked responses for P3 compo-
nent as compared to control recording in the VTA, NAc,
and PFC. The control amplitude after saline injection was
arbitrarily set as zero. The decrease in amplitude following
0.6, 2.5, and 10.0 mg/kg MPD administration was calcu-
lated as the average of four post-injection time points (10,
20, 30, and 40 min) and is presented as the mean + S.E.M.
In the VTA (Fig. 3), a single injection of 0.6 mg/kg, 2.5
mg/kg, and 10.0 mg/kg MPD attenuated the averaged sen-
sory evoked responses in dose response characteristics,
i.e., further attenuation was observed with increased dose
of MPD. Thus, the higher MPD doses (2.5 mg/kg and 10.0
mg/kg) decreased the amplitude of sensory evoked
responses for P3 component more than the 0.6 mg/kg
dose (F2,11 = 9.784, p = 0.006). Similarly, a single injection
of 0.6, 2.5, and 10.0 mg/kg MPD, i.p., also attenuated the
averaged sensory evoked responses of P3 component
recorded from the NAc and PFC in dose response charac-
teristics (Fig. 3). Similar attenuation following 0.6, 2.5,
and 10.0 mg/kg MPD were obtained for P2 and N2 com-
ponents (Table 1).
Figure 4 summarizes the effect of 0.6, 2.5, and 10.0 mg/kg
MPD for the P3 component of the sensory evoked
responses recorded from the VTA, NAc, and PFC at 10, 20,
30, and 40 min post-injection. Values are presented as the
mean + S.E.M. In general, there was not any significant
time effect found in all three brain regions following the
administration of 0.6, 2.5, and 10.0 mg/kg MPD. All four
post-injection time points exhibited similar attenuation
in amplitude from baseline following the administration
of each MPD dose in the VTA, NAc, and PFC. There was
also no time effect (e.g., recovery) found in P2 and N2
components of the averaged sensory evoked responses
(Table 2).
Figure 5 summarizes and compares the acute dose
response characteristics of component P3 of the VTA,
NAc, and PFC following the administration of 0.6, 2.5,
and 10.0 mg/kg MPD. Values are presented as the mean +
S.E.M., where * p < 0.05 as compared among VTA, NAc,
and PFC. The 0.6 mg/kg dose attenuated the sensory
evoked responses in all three sites, and the intensity of the
attenuation was similar in all of them. However, for exam-
ple, following the 2.5 mg/kg dose, the P3 component
from the PFC exhibited the most attenuated effect (65%;
F2,11 = 5.848, p < 0.05) compared to the VTA (37.8%) and
NAc (55.5%). As the MPD dosage increased to 10.0 mg/
kg, the P3 component further decreased by 56.5%, 75.0%,
and 76.5% from the VTA, NAc, and PFC recordings,
respectively, at a significant level (F2,11 = 15.73, p < 0.05).
Similar observations were obtained for the P2 and N2
components of the average sensory evoked responses
recorded from the VTA, NAc, and PFC neurons (Table 1).
Discussion
There are different approaches to assess the effects of psy-
chostimulants on animals. This study reports two
approaches – behavior and neurophysiology. Sunohara et
al. [29] proclaimed that it is important to use both behav-
ioral and neurophysiological approaches. It is known that
psychostimulants modulate the expression of the subjects'
behavior via alteration of their sensory input. In the
present study, we report behavioral as well as electrophys-
iological observations following sensory stimulation
before and after several doses of the psychostimulant
MPD. Most of the electrophysiological experiments inves-
tigating the property of MPD have been conducted in the
presence of anesthesia [4,31,32], which is known to mod-
ulate CNS activity [33], or used brain slices [34-38] to
record the effect of the drug on spontaneous activity and
the role of different neurotransmitters in MPD action.
None of the studies investigate, in freely behaving animals
previously implanted with permanent electrodes and
without the interference of anesthesia, the dose-response
characteristics on sensory input recorded simultaneously
from sites where psychostimulants are known to initiate
and/or express their effects. Thus, the objectives of the
present study were to investigate the acute dose-response
effects of MPD on animal behavior, as well as on sensory
evoked potentials from the brain areas considered to be
the sites of psychostimulant action, such as the VTA, NAc,
and PFC, in intact, non-anesthetized, freely behaving rats
previously implanted with permanent electrodes.
Thoughts were given to correlate the effects of the drug on
animal behavior to its neurophysiological responses in
specific brain areas. The present study reports four main
findings: (1) single 0.6 mg/kg MPD failed to alter locomo-
tor activity, while 2.5 and 10.0 mg/kg MPD injection elic-
ited increase in locomotor activity in a dose response
manner; (2) the amplitude of the average sensory evoked
response components (P2, N2, and P3) obtained from the
VTA, NAc, and PFC exhibited the opposite effects from the
behavior, that is, MPD elicited dose-response attenuation
to all three MPD doses in a dose-response characteristics;
(3) differences in the MPD-induced attenuation of P2,
N2, and P3 amplitudes were found among VTA, NAc, and
PFC; and (4) there was not any significant time effect in
the attenuation of P2, N2, and P3 amplitudes following
administration of 0.6, 2.5, and 10.0 mg/kg MPD during
the 40 min post drug administration.
In the behavioral dose-response experiment, the lowest
MPD dose used (0.6 mg/kg) failed to produce any signifi-
cant effect on the locomotor responses of the rats com-
pared to saline (Fig. 1). However, a single administration
of 2.5 mg/kg MPD elicited significant augmentation in the
horizontal and vertical activities. The 10.0 mg/kg MPD
induced further increase of these locomotor behaviors
compared to 2.5 mg/kg MPD. The present behavioralBehavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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shows a representative of the average (n = 50) sensory evoked field potential responses recorded in the VTA, NAc, and PFC  upon acoustic stimulation following the administration of saline (baseline) and acute MPD (0.6, 2.5, and 10.0 mg/kg, i.p.) Figure 2
shows a representative of the average (n = 50) sensory evoked field potential responses recorded in the VTA, NAc, and PFC 
upon acoustic stimulation following the administration of saline (baseline) and acute MPD (0.6, 2.5, and 10.0 mg/kg, i.p.). Time 
interval between injections was 90 min. All recordings were obtained 20 min post-injection of saline and MPD.
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observation confirms and extends previous reports of
increased locomotor activity in response to a single MPD
administration [40-44]. Increased motor activity is the
most commonly observed effect of psychostimulants in
animal models. It is an integrated response that represents
the final expression of different neuronal processes.
The same MPD doses elicited the opposite effects on the
sensory inputs recorded from the VTA, NAc, and PFC
areas. The amplitude of the sensory responses consists of
P1, N1, P2, N2, and P3 components. The cognitive proc-
esses and their underlying mechanisms associated with
each of these components have not been definitively iden-
tified. However, sensory evoked potential recording is an
approach frequently used for analyzing information
processing in the human brain [45] because these compo-
nents reflect cognitive processes at specific, neuroanatom-
ical locations [29,46]. For examples, P2 reflects feature
detection and is observed at the central and frontal areas
of the brain [47]; N2 reflects target identification when it
is observed at anterior locations of the brain [48]; and P3
reflects further processing and evaluation of the relevant
stimulus [49] and updating working memory and post
decisional processes [45]. It is largest over parietal and
central regions of the brain [45].
In general, all MPD doses attenuated the three amplitudes
(P2, N2, and P3) of the AAER in dose-response character-
istics, i.e., increasing the MPD doses further attenuated the
amplitude, except for the P2 component recorded from
the PFC following 0.6 mg/kg administration. This obser-
vation supports the findings by Arnsten and Dudley [50]
that low MPD dose improved PFC cognitive function. In
contrast to the non-significant change in locomotor activ-
ity observed after 0.6 mg/kg MPD treatment compared to
that of saline, acute administration of 0.6 mg/kg MPD
(i.p.) attenuated the amplitude of P2, N2, and P3 compo-
nents of sensory evoked field responses from the VTA,
NAc, and PFC when compared to that of saline baseline
(Fig. 2). It appears that this MPD dosage attenuated the
average acoustic evoked responses by 19.8%, 27%, and
29.5% in the VTA, NAc, and PFC, respectively, while the
same MPD dose (0.6 mg/kg) was not efficacious enough
to elicit a behavioral (locomotor) response. This attenua-
tion of sensory input persisted and became more pro-
nounced as the MPD dosage increased to 2.5 and 10.0
mg/kg (Fig. 3), while locomotor activity following these
MPD doses significantly increased with dose-response
characteristics (Fig. 1).
Methylphenidate elicits its effects on the CNS via the mes-
ocorticolimbic system. Therefore, sensory evoked poten-
Table 1: The percent decrease in amplitude from baseline of P2 and N2 components in the various brain areas of adult male WKY rats 
following a single injection of 0.6, 2.5, and 10.0 mg/kg MPD (i.p.).
Component Brain Area 0.6 mg/kg MPD 2.5 mg/kg MPD 10.0 mg/kg MPD
P2 VTA 15.3 ± 5.5% 38.8 ± 6.2% 41.3 ± 10.6%
NAc 12.5 ± 9.2% 20.5 ± 2.7% 51 ± 5.9%
PFC -11 ± 2.2% 34.3 ± 4.7% 43 ± 8.7%
N2 VTA 21.8 ± 5.9 34.8 ± 6.7% 55 ± 6 %
NAc 23.5 ± 5.9% 53.5 ± 3.2% 60 ± 2.4%
PFC 29.5 ± 7.4 65 ± 6 76.5 ± 2.7
Table 2: The effect of a single administration of 0.6, 2.5, and 10.0 mg/kg MPD on the attenuation in amplitude from baseline of P2 and 
N2 components during 10, 20, 30, and 40 min post-injection.
VTA NAc PFC
Time post-
injection
0.6 mg/kg 2.5 mg/kg 10.0 mg/kg 0.6 mg/kg 2.5 mg/kg 10.0 mg/kg 0.6 mg/kg 2.5 mg/kg 10.0 mg/kg
P2 10 min 11.0 57.0 58.0 21.0 17.0 56.0 -9.0 21.0 63.0
20 min 3.0 36.0 57.0 -12.0 28.0 61.0 -11.0 38.0 52.0
30 min 29.0 32.0 37.0 10.0 16.0 53.0 -7.0 43.0 28.0
40 min 18.0 30.0 13.0 31.0 21.0 34.0 -17.0 35 29
N 2 1 0  m i n 1 6 . 05 1 . 0 6 8 3 4 . 06 2 . 06 4 . 03 7 . 07 5 . 08 2 . 0
20 min 4.0 40.0 61.0 11.0 48.0 61.0 9.0 71.0 78.0
3 0  m i n 3 7 . 02 6 . 05 0 . 01 6 . 05 5 . 06 2 . 04 3 . 06 6 . 07 7 . 0
4 0  m i n 3 0 . 02 2 . 04 1 . 03 3 . 04 9 . 05 3 . 02 9 . 04 8 . 06 9 . 0Behavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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summarizes the percent decrease in amplitude of the sensory (acoustic) evoked responses for component P3 as compared to  control recording in the VTA, NAc, and PFC Figure 3
summarizes the percent decrease in amplitude of the sensory (acoustic) evoked responses for component P3 as compared to 
control recording in the VTA, NAc, and PFC. The control amplitude after saline injection was arbitrarily set as zero. The 
decrease in amplitude of 0.6, 2.5, and 10.0 mg/kg MPD doses was calculated as the average of four post-injection time points 
(10, 20, 30, and 40 min) and is presented as the mean + S.E.M, where *p < 0.05 as compared to 0.6 mg/kg MPD.Behavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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summarizes the effect of 0.6, 2.5, and 10.0 mg/kg MPD in the component P3 of VTA, NAc, and PFC at 10, 20, 30, and 40 min  post-injection Figure 4
summarizes the effect of 0.6, 2.5, and 10.0 mg/kg MPD in the component P3 of VTA, NAc, and PFC at 10, 20, 30, and 40 min 
post-injection. Values are presented as the mean + S.E.M.Behavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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tial responses were recorded in these brain regions. The
mesocorticolimbic pathway consists of DA neurons in the
VTA that project to the NAc and PFC [51]. Methylpheni-
date binds to DAT at the presynaptic region of these brain
areas and blocks their DA re-uptake, resulting in accumu-
lation of extracellular DA [52]. The extracellular DA act at
both presynaptic and postsynaptic receptors. The activa-
tion of presynaptic DA autoreceptors expressed by the
somatodendritic regions of DA neurons exerts a strong
inhibitory effect on the neuronal activity and transmitter
release of these neurons [53]. Thus, increased extracellular
DA level produces inhibition of the firing of DA neurons
[54-57] and may result in further attenuation from base-
line of P2, N2, and P3 components of VTA, NAc, and PFC
neurons as the MPD dosage increased in the present
study. The presence of a negative feedback mechanism
involving increased extracellular DA is also confirmed by
a study showing that when the DA-mediated feedback
inhibition was blocked by raclopride, a DA antagonist,
the psychostimulant d-amphetamine, instead of produc-
ing no effect, effectively excited the DA cells [58].
Increased extracellular DA concentration also activates
postsynaptic DA receptors and thereby enhances the
motor-activating effects [53], as observed in the behavio-
ral dose-response of MPD (Fig. 1).
An acute administration of d-amphetamine has also been
shown to excite some DA neurons recorded in the VTA
[59]. It may be that some DA neurons in the VTA, NAc,
and PFC of non-anesthetized rats exhibit two types of DA
receptors, that is, receptors that the DA causes excitation
and other receptors that the DA causes inhibitory effects
in response to psychostimulants but that the average of
these two results in an inhibitory effect. This may lead to
a plausible explanation for the differences in the MPD-
induced attenuation of N2 and P3 amplitudes among the
VTA, NAc, and PFC (Fig. 5). That is, differential popula-
tions of DA neurons that respond to DA by excitation or
inhibition are among the VTA, NAc, and PFC which affect
the net outcome. It is possible that this attenuation of sen-
sory input inhibits the inhibitory component (i.e., disin-
hibition) of the motor system and the motive circuit
nuclei, which results in locomotor activation and
improves cognition.
summarizes and compares the acute dose response characteristics of component P3 of the VTA, NAc, and PFC following the  administration of 0.6, 2.5, and 10.0 mg/kg MPD Figure 5
summarizes and compares the acute dose response characteristics of component P3 of the VTA, NAc, and PFC following the 
administration of 0.6, 2.5, and 10.0 mg/kg MPD. Values are presented as the mean + S.E.M., where * p < 0.05 as compared 
among VTA, NAc, and PFC.Behavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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The sensory evoked responses were obtained from 10 to
40 min post injection of MPD. This window for recording
was based on our previous behavioral experiment [44],
showing that the peak effect on locomotion was around
10 min and the duration was about 40 min. To our sur-
prise, the MPD effects on the sensory input in all of the
brain sites recorded remained the same during the entire
recording time (Fig. 4), suggesting that the sensitivity to
express effect of a drug between behavior and electrical
activity is different. Moreover, if there is effect on neuronal
activity, it is not necessary that the animal's behavior
expresses the drug effects.
Conclusion
Collectively, these results suggest that an acute treatment
of MPD produces electrophysiologically detectable altera-
tions at the neuronal level, as well as observable, behavio-
ral responses. It is believed that through systematic
analysis of waveforms investigators can follow attentional
processing from the early stages of initial stimulus detec-
tion to subsequent mental representation and response
execution [29]. To our knowledge, the present study is the
first to investigate the acute dose-response effects of MPD
on behavior in terms of locomotor activity and in the
brain involving the sensory inputs of VTA, NAc, and PFC
neurons in intact, non-anesthetized, freely behaving rats
previously implanted with permanent electrodes. Given
the fact that repeated exposure to psychostimulants, such
as amphetamine, cocaine, and methamphetamine, results
in elicited augmented behaviors known as behavioral sen-
sitization [13,60,61] and a variety of neuroadaptating
processes associated with addiction [62-64], it is essential
that further studies on MPD through sensory evoked
potentials recordings are necessary in order to gain further
knowledge on the mechanism of MPD action and how
the drug modulates the ADHD patient's sensation to alter
his or her behavior, as well as the mechanisms that corre-
late to locomotor activity and attentional processing,
especially in terms of chronic administration of MPD,
behavioral sensitization, and drug dependence.
Methods
Subjects
Adult male Wistar-Kyoto rats (n = 49; 65–70 postnatal
days) were obtained from Harlan (Indianapolis, IN,
USA). Upon receipt, these rats weighed 260–270 g. They
were housed in groups of two per Plexiglas cage and main-
tained on a 12-h light/dark cycle (lights on from 05:30 to
17:30 h) with an ambient temperature of 21 ± 2°C and a
relative humidity of 37% to 42%. Rats were given food
pellets and water ad libitum throughout the study. They
acclimated in this room for one week prior to any experi-
mental manipulation. All experiments were carried out in
accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and our insti-
tution's Animal Welfare Committee Guidelines.
Drugs
Methylphenidate hydrochloride (MPD) was a gift from
Mallinckrodt Inc. (St. Louis, MO, USA). There are not uni-
versally recognized dosage guidelines and blood levels to
achieve optimal treatment with MPD [65]. A study of 289
patients treated with MPD reported that the range of doses
ingested in these patients was from 0.06 – 29.3 mg/kg and
that the majority of the patients were treated with 1.0 –
3.0 mg/kg MPD [66]. Generally, intraperitoneal (i.p.)
administration leads to peak plasma level of MPD much
higher and faster than oral administration. The binding of
MPD to dopamine transporter (DAT) increases DA in the
synaptic cleft in intraperitoneal administration [67,68];
while oral MPD application elevates mainly norepine-
phrine (NE), in addition to DA [68], which improves cog-
nitive function through α2 adrenoceptors and dopamine
D1 receptor actions [50] without increasing locomotion.
Drug effects in rodents often require higher doses on an
mg/kg basis than in humans because rodents exhibit a
more rapid metabolism [52]. In selecting the equivalent
dose for rats as compared to dosage in humans, we must
take into account these differences in the pharmacokinet-
ics between humans and rodents, which include route of
administration, absorption, volume, metabolism, and
excretion [67,69,70].
In our preliminary behavioral experiment, we used 0.1,
0.6, 1.2, 2.5, 5.0, 10.0, 20.0, and 40.0 mg/kg MPD (i.p.).
The three initial MPD doses (0.1, 0.6, and 1.2 mg/kg) did
not exhibit any effect on locomotor activity, while the 2.5
mg/kg dose increased locomotion in dose-response char-
acteristics [42]. Therefore, in the present study, we selected
three MPD doses. The first is 0.6 mg/kg, which does not
exhibit any effect in locomotor activity. The second and
third doses are 2.5 and 10.0 mg/kg, which fall within the
clinical range in treating children and adult with ADHD
[50,52,60,61,67,68]. The drug was dissolved in 0.9%
saline, and the dosages were calculated as free-base. All
injections were administered intraperitoneally (i.p.)
between 07:00 h and 12:00 h and equalized to a volume
of 0.8 ml with 0.9% saline so that the total volume of each
injection in all animals would be the same.
Behavioral experiments
Protocol
Rats (n = 39) were randomly divided into four different
treatment groups (saline, 0.6, 2.5, or 10.0 mg/kg MPD).
Each rat was individually placed inside an automated
activity monitoring cage located in the sound-attenuated,
temperature-, and humidity-controlled room to habituate
for 24 h prior to the first experimental day (Day 1). The
activity monitoring cage now served as the animal's homeBehavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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cage for the next two days. All rats received an injection of
0.9% saline on experimental day 1. On experimental day
2, Groups I (n = 8), II (n = 11), III (n = 12) and IV (n = 8)
rats received saline, 0.6, 2.5, and 10.0 mg/kg MPD, respec-
tively. Locomotor activities were recorded for 2 h follow-
ing saline/drug administration on each of the two
experimental days.
Apparatus
Each activity monitoring cage (Accuscan, Columbus, OH,
USA) consisted of a clear, acrylic open-field box (40.5 ×
40.5 × 31.5 cm) fitted with two levels of infrared motion
sensors located 6 and 12.5 cm above the floor of the box.
This system checked for interruptions of each infrared
beam at a frequency of 100 Hz. Interruption of any beam
was recorded as an activity score. Simultaneous interrup-
tions of two or more consecutive beams separated by at
least 1 sec were recorded as a movement. Cumulative
counts were compiled and downloaded every 10 min into
the OASIS data collection software that organized and dif-
ferentiated these counts into various locomotor indices.
Two locomotor indices were evaluated: horizontal activity
and vertical activity. Horizontal activity measures the total
number of beam interruptions that occurred at the lowest
tier (horizontal sensor) during a given sample period. Ver-
tical activity measures the total number of beam interrup-
tions that occurred in the vertical sensor (upper tier)
during a given sample period which counted mainly rear-
ing.
Data analysis
The saline treated rats served as the control group. In addi-
tion, each animal served as its own control. Therefore, in
addition to examining and comparing the cumulative
drug effects observed between treatment groups, the
responses of the animals to the drugs were also evaluated
by having each animal within a treatment group served as
its own control to eliminate any handling and injection
effects. This was determined by subtracting the activity
score of the 2-h after saline injection (experimental day 1)
from that of the 2-h after drug injection on experimental
day 2. Thus, the activity of saline injection served as the
baseline and the absolute change in activity from saline
represented the effect of the drugs. In a previous study
[44], it was found that the duration of MPD on locomo-
tion was 50–90 min; therefore, a 120 min cumulative
activity was recorded after each treatment. Observations
within a treatment group and between treatment groups
were analyzed using Analysis of Variance (ANOVA: treat-
ment days and drug dose) and post-hoc Fischer's LSD
method. Statistical significance was set at p < 0.05 for all
comparisons.
Neurophysiological experiments
Surgical procedure
After 3–7 days of acclimation upon arrival from the ven-
dor, adult male WKY rats (n = 10) were anesthetized with
50 mg/kg pentobarbital (i.p.) and placed in a stereotaxic
apparatus. A 2 cm skin incision was made, and the skull
was exposed. A hole of 1 mm in diameter was drilled to
insert an electrode into selected brain areas. Brain coordi-
nates derived from Paxinos and Watson [71] atlas were
used to implant stainless steel semi-microelectrodes (80
µm in diameter) bilaterally in the prefrontal cortex (PFC:
Bregma 2.7 mm, lateral 0.6 mm, depth 3.8 mm), nucleus
accumbens (NAc: Bregma 1.7 mm, lateral 1.6 mm, depth
6.8 mm), and ventral tegmental area (VTA: Bregma -4.8
mm, lateral 1.0 mm, depth 8.3 mm). An electrode was
also implanted in the nasal skull as a reference. All elec-
trodes were fixed permanently to the skull with dental
acrylic cement and attached to terminals in an Amphenol
plug.
Sensory evoked field potentials
Two days after recovery from the implantation of elec-
trodes, rats were placed inside a cubic Plexiglas box (23
cm3) located within a sound-insulated, electrophysiologi-
cal test chamber for habituation to the testing environ-
ment. Each rat received a daily 30-min habituation period
in this box for two consecutive days prior to the experi-
mental day.
On experimental day (5 to 7 days after electrode implan-
tation), the rat was put back inside the Plexiglas box to
habituate for 30 min prior to experimentation. The elec-
trodes in the rat's head were encased in an Amphenol
plug, which was connected to a Grass P511 amplifier by
means of low noise leads via a commutator mounted on
a counter-balanced arm that allowed the animal to move
freely in the Plexiglas box. From the amplifier, the neuro-
nal activities were monitored with multi-beam oscillo-
scopes and connected to the Micro 1041 (Cambridge
Electronic Design, Cambridge, England). The Micro 1041
was connected to a PC computer equipped with the Spike
2 program (Cambridge Electronic Design, Cambridge,
England) for digitizing, averaging, and storing the data for
off-line evaluation. Acoustic stimulation was in the form
of 'clicks' produced by a Grass AC-5 audio-stimulator. The
remote speaker (10 cm in diameter) was placed 1.0 cm
from the Plexiglas box. A digitimer device (model # 3290)
triggered the acoustic stimulator and all other equip-
ments. At every 2.4 second, a stimulus was presented. Four
trains, each consisted of 50 acoustic stimuli, were pre-
sented at 5-min intervals for control (saline) recordings
and resumed every 10-min after each drug injection for an
additional four trains of 50 acoustic stimulations. Each
stimulating session lasted 2 min (50 stimuli every 2.4 sec
= 120 sec = 2 min). Sensory evoked field potentials wereBehavioral and Brain Functions 2006, 2:3 http://www.behavioralandbrainfunctions.com/content/2/1/3
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simultaneously recorded from the VTA, NAc, and PFC
after saline, 0.6, 2.5, and 10 mg/kg MPD injection (i.p.).
After saline injection and control recording, each animal
was injected with 0.6, 2.5, and 10.0 mg/kg. Time between
injections was 90 min. This time interval was based on our
previous behavioral experiment [44] that demonstrated
that after 50 to 70 min after the administration of 2.5 and
10.0 mg/kg MPD the locomotor activity returned to base-
line. Therefore, in the present study, we used 90 min
between injections to reduce the effects of the previous
dose.
Data analysis
Fifty sensory evoked responses were averaged off-line
using the Spike 2 program (Cambridge Electronic Design,
Cambridge, England). For every acoustic stimulus, four
averages were calculated after every saline/MPD injection.
Each averaged sensory evoked response was evaluated in
terms of amplitude of the characteristic components from
peak to peak. The acoustic sensory evoked response on a
rat exhibited five main components: P1, N1, P2, N2, and
P3. The 'P' indicates positive amplitude; the 'N' indicates
negative amplitude. The integers indicate the first, second,
or third component, i.e., P1 refers to the first positive
component of the evoked field response amplitude. The
P1 and N1 components were not consistent within and
between animals and therefore were not analyzed. The P2,
N2, and P3 components were the most consistent compo-
nents within and between animals in the three selected
brains areas of this study and therefore were evaluated.
Changes induced by the three doses of MPD were evalu-
ated by comparing the component amplitudes averaged
following drug injection recording to that of the control
(saline) recording. A mean amplitude change ± 2 standard
error (either increase or decrease) in comparison to the
control recording was regarded as a significant change
[72,73]. Each animal served as its own control. Compari-
son between groups was performed with ANOVA with
95% confidence level.
Histological verification of electrode placement
At the end of the experiment, rats were overdosed with
200 mg/kg sodium pentobarbital. A lesion was placed at
the tip of each electrode by passing a 50 µA direct current
for 30 seconds. The brain was then transcardially perfused
with a solution of 10% formalin containing 3% potas-
sium ferrocyanide. Brain sections were cut serially at a
thickness of 80–100 µ using a vibrotome (OTS-3000-03;
FHC, Brunswick, ME, USA) and stained with Cresyl violet.
The position of the electrode tips was identified by the
location of the lesion and Prussian blue spot.
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